contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nexstim-receives-an-upgrade-order-from-a-german-university-hospital

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Nexstim on vuonna 2000 perustettu suomalainen kansainvälisillä markkinoilla toimiva terveysteknologiayhtiö, jonka tuotteet mahdollistavat aivokuoren toiminnallisten alueiden kartoituksen ja halutun aivoalueen tarkan stimuloinnin sähkökentän avulla. Nexstimin liiketoiminta jakaantuu diagnostiikka- (Navigated Brain Stimulation NBS) ja terapia (Navigated Brain Therapy NBT) -liiketoimintoihin. Yhtiö on hiljattain alkanut tarjota asiakkailleen myös yhdistelmälaitteistoja, jotka sisältävät sekä NBS- että NBT-toiminnallisuudet. Nexstimillä on asiakkaita useassa kymmenessä maassa.

Minulla ei kyllä näy viimeisimmän kierroksen summaa tai päivämäärää tuola linkin takana?

Kiitos – hyvin etsitty / löydetty! Eli 6:lta varhaisen vaiheen Venture Capital sijoittajilta on tullut (ko.lähteen mukaan) rahaa 9 M $. Kierros päättynyt 28.11.2024 (Copilot mukaan?) Aikaisempi 9 /2023 päättynyt siemenrahoitus arvo 1,5 M $ ” Sinaptica Therapeutics has raised over time = 10.5M $”

https://pitchbook.com/profiles/company/528316-48#overview tämän mukaan Sinaptican rundi olisi nyt completed

Kiitos @Mark_Renton! Nexstimin koko tiimi on tehnyt kovasti töitä tämän eteen ja hienoa nähdä sen tuloksena tällainen huikea viikko uusien tilausten osalta.

Vuoden kurssinousija Hesulissa, eikä ihan syyttä. (Joo, vähän nollapostaus, mutta Nexstim-sijoittajille ei ihan nolla-arvoinen sisältö tässäkään heitossa.)

Tämä viikko meni aika hyvin kauppojen suhteen. Onnittelut @Mikko_Karvinen_Nexst ja koko Nexstimin jengi, nyt on hyvä draivi päällä  https://www.nexstim.com/news-and-events/news/press-release/delve-psychiatry-in-nevada-united-states-orders-nexstim-nbs-5-system-1

Viime vuonna oli vuoden viime päivinä 5 vastaavaa tiedotetta, joissa taisi olla yhteensä 6 laitetta. Osa tuli tosiaan joulun välipäivinä. Aiemmin ei muistini mukaan ihan vastaavaa tykitystä ole nähty.

Nexstim

Press release, Helsinki, 16 December 2024 at 9 AM (EET) Nexstim Receives an Upgrade Order from a German University HospitalNexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an upgrade...

Press release, Helsinki, 16 December 2024 at 9 AM (EET)&nbsp;Nexstim Receives an Upgrade Order from a German University HospitalNexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an upgrade order for an NBS System 5 from a university hospital in Germany. The hospital is an existing customer that is upgrading their Nexstim system.Nexstim’s NBS (Navigated Brain Stimulation) System 5 is CE marked and FDA approved for presurgical mapping of the speech and motor cortices of the brain. In addition to its motor and speech mapping features, this specific system also includes therapeutic capabilities that allow the system to be used for the treatment of major depression and chronic neuropathic pain.Mikko Karvinen, CEO of Nexstim, comments: “This customer represents the neurosurgery community that we have been successfully serving for long. We value the work that our long-time customers have done over the years in terms of both treating patients and conducting research. We are about to enter a new phase with the distribution of our diagnostics solutions in the German market, but the strong relationships with these customers remain important for us.”Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO+358 50 326 4101mikko.karvinen@nexstim.com&nbsp;About Nexstim Plc Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.Nexstim shares are listed on Nasdaq First North Growth Market Finland.For more information, please visit <a href="http://www.nexstim.com/">www.nexstim.com </a> <div> <hr> <div>Attachments</div> <div><a href="https://storage.googleapis.com/inderes-widgets-prod-assets/nexstim/attachments/8d33e759-57ed-4772-b79a-1578aaabe735/nexstim-plc-press-release-germany-order-16122024-final.pdf">Nexstim Plc_Press release_Germany order_16122024_FINAL.pdf</a></div> </div>

Pysy ajantasalla Inderesin uutiskirjeillä